Phase Ib/II Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Initial Efficacy of STSA-1002 Injection in Patients with Acute Respiratory Distress Syndrome
Latest Information Update: 24 Nov 2024
At a glance
- Drugs STSA-1002 (Primary)
- Indications Adult respiratory distress syndrome; Pneumonia
- Focus Therapeutic Use
- Sponsors Staidson Beijing BioPharmaceuticals
Most Recent Events
- 14 Nov 2024 Planned number of patients changed from 90 to 60.
- 11 Dec 2023 Status changed from not yet recruiting to recruiting.
- 19 Sep 2023 New trial record